HOME >> MEDICINE >> NEWS
OHSU Scientists Begin Human Trials Of A Drug Aimed At The Underlying Cause Of Chronic Myelogenous Leukemia

For the first time, patients with a specific form of leukemia will receive an investigational drug therapy aimed precisely at the molecules causing their cancer. The first patient, 68-year-old Bud Romine from Tillamook, Ore., will take his first dose of the experimental drug on Thursday, June 25, 1998, at Oregon Health Sciences University.

The often fatal blood disease is called chronic myelogenous leukemia and strikes about 6,000 Americans annually. "The highly targeted drug eliminates leukemia cells in mice, and will be used for the first time in humans this summer," explained Brian Druker, M.D., principal investigator of the trial and associate professor of hematology and medical oncology at Oregon Health Sciences University.

Until now, patients with chronic myelogenous leukemia have been treated with chemotherapy aimed at killing rapidly dividing cells or they have undergone bone marrow transplantation aimed at replacing their diseased marrow.

"This experimental therapy is different than chemotherapy because it targets leukemia cells and leaves normal cells alone," explained Druker.

"When I was diagnosed with leukemia four years ago I began chemotherapy," said Romine. "But I never went into remission. Then I read about Brian Druker's work in The Oregonian and I wrote him a letter."

Romine will be the first of about 50 patients to enter the clinical trial. Within a year, physicians expect to determine the success of the therapy. All patients in the trial will receive the drug, and dosages will be escalated until either significant benefits or side effects appear.

The multicenter trial was designed by the Oregon Cancer Center based at OHSU and will also be conducted at UCLA and M.D. Anderson Medical Center in Texas.

"The commitment of the Oregon Cancer Center to controlling cancer and leukemia is based upon two fundamental premises. First, you can't prevent or cure cance
'"/>

Contact: Henry Sessions
sessionh@ohsu.edu
503-494-8231
Oregon Health & Science University
25-Jun-1998


Page: 1 2 3 4

Related medicine news :

1. Scientists replicate hepatitis C virus in laboratory
2. Scientists identify brain regions that decide where we look
3. Scientists uncover new mechanism for the amygdala in fear recognition
4. Scientists identify protein critical to melanoma growth
5. Scientists discover recipe for life: eating the Polymeal cuts heart disease by 76%
6. Scientists study fish oil diet in bid to cut heart attack risks
7. Scientists discover enzyme crucial to the transportation of proteins within cells
8. Scientists turn on the gender lens on cardiovascular disease research
9. Scientists stalk PPAR-gamma, find novel cancer connection
10. Scientists align billion-year-old protein with embryonic heart defects
11. Scientists pinpoint flaw, offer new promise for stroke treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... 26, 2020 , ... Medisend College of Biomedical Engineering Technology, ... training that prepares graduates for professional careers as field service engineers and biomedical ... Trustees. , Ms. Williams currently serves as Associate Vice Chancellor of Workforce and ...
(Date:6/28/2020)... ... June 27, 2020 , ... The FSHD ... full-day educational conference in the organization’s history. The online conference takes the place ... which was cancelled this year due to COVID-19. Nearly 300 individuals and families ...
(Date:6/24/2020)... ... June 24, 2020 , ... At Allerio we have chosen to do things ... communications. We knew it had to be portable, it had to be reliable, it ... to work. , We are proud to announce that Allerio has passed all FCC ...
(Date:6/24/2020)... Berkeley, CA (PRWEB) , ... June 24, 2020 ... ... offers life-changing frenectomies for those with lip ties and tongue ties ... Course, Dr. Chertok offers a collaborative approach to care with multispecialty teams including ...
(Date:6/23/2020)... ... June 22, 2020 , ... In its latest report on companion ... the market for tests tied to therapeutic selection or effectiveness. To get a ... well as pharmaceutical companies serving them to determine recent market trends. The analysts ...
Breaking Medicine News(10 mins):
(Date:6/24/2020)... ... June 24, 2020 , ... The Safe Boating Campaign, a worldwide effort ... under the influence, or BUI, is the leading contributing factor in recreational boater deaths, ... corner, and unfortunately has become known for drinking and boating, and deadly accidents,” said ...
(Date:6/23/2020)... Ind. (PRWEB) , ... June ... ... LLC ("Lighthouse" or the "Company"), a leading provider of center-based, Applied Behavioral ... (“ATS”), a rapidly-growing, center-based ABA provider in the greater-Indianapolis market. This acquisition ...
(Date:6/19/2020)... (PRWEB) , ... June 19, 2020 , ... The Covid-19 ... a top priority. Establishing a safe environment and compliant workforce is critical in the ... SupplyPro is offering its popular SupplyBay vending machine below cost for a limited time ...
Breaking Medicine Technology:
Cached News: